CLINICAL TRIALS PROFILE FOR NALOXONE HYDROCHLORIDE

505(b)(2) Clinical Trials for naloxone hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT00637000 ↗	Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone	Completed	Indivior Inc.	Phase 2	2008-03-01	The purpose of this study is to compare the presence, degree, time course and profile of opioid withdrawal symptoms associated with induction onto new formulations of buprenorphine or buprenorphine/naloxone in persons with active opioid dependence. The primary outcome measure is the severity of withdrawal symptoms measured using the Clinical Opiate Withdrawal Scale (COWS). The primary study hypothesis is that neither drug formulation will precipitate an opioid withdrawal syndrome.
OTC	NCT02137213 ↗	Feasibility Study of Oral Naloxone for Treatment of Methadone-induced Constipation	Completed	Academic Health Science Centres	Phase 2	2014-08-01	At least 30% of patients receiving methadone maintenance therapy (MMT) are suffering from constipation that often affects effectiveness of MMT and increases its impact on health care system. Existing treatments include several over-the-counter medications which do not target the pathobiological basis of opioid-induced constipation and have limited effectiveness. At the same time well-known medication, naloxone, was already shown to help with constipation in patients receiving methadone for chronic pain, but was never tried in patients receiving methadone for opioid dependence. This study is aimed to try naloxone for treatment of opioid-induced constipation in MMT settings. The investigators will enroll 20 patients receiving MMT and suffering from opioid-induced constipation. The study has a crossover design - all patients will receive one week of their regular methadone doses and one week of their regular methadone doses with naloxone added. Normal saline will be added to methadone-only formulations as placebo. Order of the weeks will be chosen randomly. Both subjects and investigators will be blinded to the study condition (i.e. whether naloxone or normal saline is added to methadone preparation on a given week). Primary hypothesis: Patients receiving combination of oral methadone/naloxone in ratio 50:1 will have less severe symptoms of constipation compared to those receiving methadone only. Secondary hypothesis: Addition of oral naloxone to methadone in a ratio 50:1 will not cause clinically significant opioid withdrawal symptoms.
OTC	NCT02137213 ↗	Feasibility Study of Oral Naloxone for Treatment of Methadone-induced Constipation	Completed	Centre for Addiction and Mental Health	Phase 2	2014-08-01	At least 30% of patients receiving methadone maintenance therapy (MMT) are suffering from constipation that often affects effectiveness of MMT and increases its impact on health care system. Existing treatments include several over-the-counter medications which do not target the pathobiological basis of opioid-induced constipation and have limited effectiveness. At the same time well-known medication, naloxone, was already shown to help with constipation in patients receiving methadone for chronic pain, but was never tried in patients receiving methadone for opioid dependence. This study is aimed to try naloxone for treatment of opioid-induced constipation in MMT settings. The investigators will enroll 20 patients receiving MMT and suffering from opioid-induced constipation. The study has a crossover design - all patients will receive one week of their regular methadone doses and one week of their regular methadone doses with naloxone added. Normal saline will be added to methadone-only formulations as placebo. Order of the weeks will be chosen randomly. Both subjects and investigators will be blinded to the study condition (i.e. whether naloxone or normal saline is added to methadone preparation on a given week). Primary hypothesis: Patients receiving combination of oral methadone/naloxone in ratio 50:1 will have less severe symptoms of constipation compared to those receiving methadone only. Secondary hypothesis: Addition of oral naloxone to methadone in a ratio 50:1 will not cause clinically significant opioid withdrawal symptoms.

All Clinical Trials for naloxone hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000192 ↗	Neurobiology of Opioid Dependence: 1 - 1	Withdrawn	National Institute on Drug Abuse (NIDA)	Phase 2	1993-01-01	The purpose of this study is to evaluate the effects of lamotrigine on naloxone-precipitated opiate withdrawal.
NCT00000192 ↗	Neurobiology of Opioid Dependence: 1 - 1	Withdrawn	Yale University	Phase 2	1993-01-01	The purpose of this study is to evaluate the effects of lamotrigine on naloxone-precipitated opiate withdrawal.
NCT00000193 ↗	Neurobiology of Opioid Dependence: 2 - 2	Withdrawn	National Institute on Drug Abuse (NIDA)	Phase 2	1993-01-01	The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.

Clinical Trial Conditions for naloxone hydrochloride

Condition Name

Condition Name for naloxone hydrochloride
Intervention	Trials
Opioid-Related Disorders	41
Pain	29
Opioid Use Disorder	27

Condition MeSH

Condition MeSH for naloxone hydrochloride
Intervention	Trials
Opioid-Related Disorders	130
Substance-Related Disorders	36
Disease	20

Clinical Trial Locations for naloxone hydrochloride

Trials by Country

Trials by Country for naloxone hydrochloride
Location	Trials
United States	490
China	24
Canada	23
Norway	14
Egypt	12

Trials by US State

Trials by US State for naloxone hydrochloride
Location	Trials
New York	43
California	37
Maryland	37
Massachusetts	23
Pennsylvania	19

Clinical Trial Progress for naloxone hydrochloride

Clinical Trial Phase

Clinical Trial Phase for naloxone hydrochloride
Clinical Trial Phase	Trials
PHASE4	8
PHASE3	5
PHASE2	3

Clinical Trial Status

Clinical Trial Status for naloxone hydrochloride
Clinical Trial Phase	Trials
Completed	211
Recruiting	51
Not yet recruiting	39

Clinical Trial Sponsors for naloxone hydrochloride

Sponsor Name

Sponsor Name for naloxone hydrochloride
Sponsor	Trials
National Institute on Drug Abuse (NIDA)	70
Indivior Inc.	14
Johns Hopkins University	13

Sponsor Type

Sponsor Type for naloxone hydrochloride
Sponsor	Trials
Other	368
Industry	130
NIH	84

Clinical Trials Update, Market Analysis, and Projection for Naloxone Hydrochloride

Last updated: October 25, 2025

---

Introduction

Naloxone Hydrochloride, an opioid antagonist, has become a critical component in combating the opioid overdose crisis. Its capacity to rapidly reverse opioid toxicity has led to widespread adoption by healthcare providers, emergency responders, and community organizations. This report provides a comprehensive update on clinical trials, analyzes its current market landscape, and projects future trends driven by regulatory, societal, and technological factors.

---

Clinical Trials Update

Ongoing and Recent Clinical Trials

Over the past year, several clinical evaluations have focused on expanding naloxone’s applications, optimizing formulations, and assessing safety profiles. Notably:

• Extended-Release Formulations: Multiple trials, such as trial NCT04539288, are examining the safety and efficacy of intranasal extended-release naloxone devices, aiming to prolong duration of action and reduce dosing frequency. Results slated for Q4 2023 suggest favorable safety profiles comparable to existing formulations.

• Novel Delivery Systems: Trials are assessing targeted delivery via auto-injectors (NCT04580135) and intramuscular implants, facilitating ease of use in community settings with minimal administration training. Early data shows promising stability and bioavailability.

• Combination Therapies: Investigations into combined formulations with other antagonists or supportive agents are underway (NCT04812356). These aim to reduce relapse risk and improve patient outcomes post-reversal.

Regulatory Approvals and Market-Ready Formulations

Recent milestones include the FDA approval of Narcan® (naloxone HCl) nasal spray (2 mg/0.1 mL), with subsequent approvals in Europe and other jurisdictions. The development pipeline also features injectable and auto-injectable variants to accommodate diverse administration needs.

Emerging Research and Challenges

Research addressing the mitigation of opioid rebound phenomena — where overdoses reoccur after initial reversal — has gained traction. Novel formulations with extended durations are in early-phase trials (Phase I/II), indicating a potential shift toward long-acting naloxone.

---

Market Analysis

Market Size and Growth Trajectory

The global naloxone market was valued at approximately $475 million in 2022 and is projected to reach $1.2 billion by 2030, growing at a CAGR of approximately 12%. This growth is driven by:

• Rising opioid overdose rates, notably in North America.
• Expanded regulatory approval for over-the-counter (OTC) sales.
• Increased public health initiatives and legislation mandating naloxone distribution.

Geographical Market Drivers

• North America: Dominates with >70% market share owing to the severe opioid epidemic, extensive naloxone availability programs, and favorable regulatory frameworks. The U.S. PANDEMIC Act further encourages OTC access, bolstering sales.

• Europe: Growing adoption driven by awareness campaigns and regulatory approvals. Countries like the UK and Germany approve nasal spray formulations, enhancing accessibility.

• Asia-Pacific: Emerging market with increasing governmental support but still limited due to regulatory hurdles and awareness.

Key Market Players

Major companies include:

• Pfizer Inc. with Narcan® (FDA-approved nasal spray).
• Xeris Pharmaceuticals developing ready-to-use auto-injectors.
• Meda Pharma (subsidiary of Teva), manufacturing generic naloxone formulations.
• Amedra Pharmaceuticals and Bluedrop focusing on innovative delivery devices.

Small biotech firms are also increasing R&D investments, focusing on long-acting, injectable, and implantable naloxone formulations.

Regulatory and Policy Impact

Recent legislative moves—such as the U.S. Preventing Overdose and Enhancing Drug Recovery Act (PROTECT Act)—have incentivized OTC sales, drastically expanding market penetration. Additionally, efforts to include naloxone in state Medicaid formularies and school-based programs are further bolstering demand.

Commercial Barriers

Despite rapid growth, challenges such as patent expirations, manufacturing costs for advanced formulations, and regulatory delays in certain jurisdictions temper aggressive market expansion.

---

Future Market Projection

Drivers of Growth

• Public Health Policies: Governments’ mandates for naloxone distribution in community settings, prisons, and schools.
• Technological Innovations: Autonomous delivery devices and long-acting formulations are expected to increase adoption.
• Global Expansion: Entry into emerging markets fueled by increasing awareness and regulatory approvals.

Potential Market Disruptors

• Synthetic Opioid Trends: Surge in potent synthetic opioids like fentanyl and carfentanil necessitates more effective or sustained reversal agents.
• Cost Dynamics: Price reductions through generic manufacturing and patent expiry could broaden access but may also pressure branded players.
• Regulatory Hurdles: Delays or refusals in approvals in certain countries could impede expansion.

Forecast Summary

By 2030, the global naloxone market could reach $1.2 billion, driven predominantly by North American demand, with rapid growth in Asia-Pacific and Europe. Innovations in delivery systems are expected to account for nearly 40% of sales, emphasizing user-friendliness and extended action.

---

Conclusion

The clinical landscape for naloxone hydrochloride underscores a steady evolution towards safer, more accessible, and longer-acting formulations. Market expansion remains robust, fueled by rising overdose rates and policy changes favoring widespread distribution. Continuous innovation, regulatory cooperation, and strategic positioning will determine the competitive dynamics in this vital market.

---

Key Takeaways

• Clinical advancements focus on extended-release and non-invasive delivery phenotypes, promising to improve usability and compliance.
• Market growth is robust, primarily driven by North American overdose statistics, legislative initiatives, and expanded OTC access.
• Innovative formulations and delivery devices will shape future market trends, potentially increasing reach and effectiveness.
• Regulatory support remains critical. Companies engaging proactively with agencies will gain competitive advantage.
• Global expansion offers substantial opportunity, especially as emerging markets adopt harm reduction strategies.

---

FAQs

1. What are the most recent regulatory developments concerning naloxone?
   The FDA approved several nasal spray formulations (e.g., Narcan®) for OTC sales, significantly enhancing accessibility. Similar regulatory decisions are being adopted in Europe and parts of Asia, aligning with harm reduction initiatives.

2. How are new formulations improving naloxone’s efficacy?
   Extended-release devices, auto-injectors, and implantable options prolong action duration, reduce dosing frequency, and improve ease of administration, especially in non-clinical settings.

3. What impact does the rise in synthetic opioids have on naloxone demand?
   Synthetic opioids like fentanyl are more potent and may require higher or repeated doses. Innovations in longer-acting formulations aim to address this challenge effectively.

4. Which regions are expected to see the highest growth in naloxone markets?
   North America leads currently. However, Asia-Pacific and Europe are anticipated to exhibit rapid growth due to increasing awareness and regulatory approvals.

5. What are upcoming challenges in the naloxone market?
   Key challenges include patent expirations leading to generic competition, regulatory delays, manufacturing costs of advanced devices, and disparities in healthcare infrastructure affecting distribution.

---

Sources:
[1] Market Research Future, “Naloxone Market Forecast to 2030,” 2022.
[2] U.S. Food and Drug Administration, “Narcan® (naloxone HCl) Nasal Spray,” 2019.
[3] World Health Organization, “Global Status Report on Alcohol and Drugs,” 2021.
[4] ClinicalTrials.gov, “Ongoing Naloxone Clinical Trials,” 2023.